Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Drug repurposing accelerates the path from discovery to the clinic, offering particular promise for rare, neglected, oncologic, and neurodegenerative diseases. Learn how we can help at bbcrconsulting.com
  • Is Your Drug Development Strategy Built for Tomorrow’s Success?
  • BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.
  • Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.
  • Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.

RSS Nasdaq Globe Newswire

  • Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting December 5, 2025
  • $3.45 Bn Bioburden Testing Markets - Global Forecasts from 2025 to 2030: Opportunities Arise from Industry Expansion, Compliance Needs, and Innovation, Despite Challenges December 5, 2025
  • $26.29 Bn Biochips Markets - Forecasts from 2025 to 2030: Opportunities in Diagnostics, Drug Discovery, and Personalized Medicine, with Significant Potential in Emerging Markets December 5, 2025
  • Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview December 4, 2025
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2025 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs